DS-2969b | CAS#2092352-48-0| GyrB/ParE inhibitor

MedKoo Cat#: 464777 | Name: DS-2969b

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DS-2969b is a GyrB/ParE inhibitor that is currently under clinical development for the treatment of Clostridium difficile infection (CDI). DS-2969b inhibited the supercoiling activity of C. difficile DNA gyrase. DS-2969b showed potent in vitro activity against C. difficile clinical isolates with a MIC90 of 0.06 μg/ml, which was 2-, 32-, and 16-fold lower than the MIC90s of fidaxomicin, vancomycin, and metronidazole, respectively.

Chemical Structure

DS-2969b

CAS#2092352-48-0

Theoretical Analysis

MedKoo Cat#: 464777

Name: DS-2969b

CAS#: 2092352-48-0

Chemical Formula: C17H25ClN6O3S

Exact Mass: 428.1397

Molecular Weight: 428.94

Elemental Analysis: C, 47.60; H, 5.88; Cl, 8.26; N, 19.59; O, 11.19; S, 7.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DS-2969b; DS2969b; DS 2969b;

IUPAC/Chemical Name

4-chloro-5-ethyl-N-((3S,4R)-1-(5-(2-hydroxypropan-2-yl)-1,3,4-thiadiazol-2-yl)-3-methoxypiperidin-4-yl)-1H-imidazole-2-carboxamide

InChi Key

RFKLYBAHWNXIDR-MNOVXSKESA-N

InChi Code

InChI=1S/C17H25ClN6O3S/c1-5-9-12(18)21-13(19-9)14(25)20-10-6-7-24(8-11(10)27-4)16-23-22-15(28-16)17(2,3)26/h10-11,26H,5-8H2,1-4H3,(H,19,21)(H,20,25)/t10-,11+/m1/s1

SMILES Code

CO[C@@H]1[C@H](NC(C2=NC(Cl)=C(CC)N2)=O)CCN(C3=NN=C(C(C)(C)O)S3)C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 428.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kullar R, Tran MN, Goldstein EJC. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). J Exp Pharmacol. 2020 Oct 9;12:371-384. doi: 10.2147/JEP.S242959. PMID: 33116952; PMCID: PMC7553590. 2: Tran MN, Kullar R, Goldstein EJC. Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opin Investig Drugs. 2019 Apr;28(4):323-335. doi: 10.1080/13543784.2019.1581763. Epub 2019 Feb 26. PMID: 30753786. 3: Tyrrell KL, Citron DM, Merriam CV, Leoncio E, Goldstein EJC. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. Anaerobe. 2018 Dec;54:39-41. doi: 10.1016/j.anaerobe.2018.04.010. Epub 2018 Apr 13. PMID: 30096588. 4: Kumar M, Mathur T, Joshi V, Upadhyay DJ, Inoue SI, Masuda N. Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota. Anaerobe. 2018 Jun;51:120-123. doi: 10.1016/j.anaerobe.2018.04.017. Epub 2018 May 2. PMID: 29758524. 5: Dennie J, Vandell AG, Inoue S, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Uchiyama M, Yamada M, Senaldi G. A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor. J Clin Pharmacol. 2018 Dec;58(12):1557-1565. doi: 10.1002/jcph.1151. Epub 2018 May 10. PMID: 29746725. 6: Barman TK, Kumar M, Mathur T, Namba E, Singh D, Chaira T, Kurosaka Y, Yamada M, Upadhyay DJ, Masuda N. In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2018 May 25;62(6):e02556-17. doi: 10.1128/AAC.02556-17. PMID: 29610202; PMCID: PMC5971602. 7: Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G. Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02537-17. doi: 10.1128/AAC.02537-17. PMID: 29439973; PMCID: PMC5923173. 8: Mathur T, Barman TK, Kumar M, Singh D, Kumar R, Khera MK, Yamada M, Inoue SI, Upadhyay DJ, Masuda N. In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17. doi: 10.1128/AAC.02157-17. PMID: 29439962; PMCID: PMC5913969.

View History

Description:

Chemical Structure

Theoretical Analysis

Price and Availability

Preparing Stock Solutions

View History

DS-1558

Tryptophyl-leucyl-glutamic acid

Tryparsamide hemihydrate

DDD86481 Tosylate

MTP-1307

DDR Inhibitor 4

Error message: